Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3876602 in healthy volunteers
NCT06007638Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3876602 (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events Related to Study Drug at 28 weeks. Started Aug 2023; status: completed.
02
Drugs
LY3876602
Beyond the preview
Go deeper on NCT06007638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007638.